Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A

As of June 30, 2026, Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A carries a market capitalization of 8.35B, placing it among publicly traded companies globally. Its enterprise value stands at 8.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A's next confirmed earnings release is scheduled for April 23, 2027.

As of June 30, 2026, Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A has 950.40M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A maintains a current ratio of 3.04, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A recorded 45.23M in income tax expense.

As of the close on October 23, 2026, Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A's stock has declined approximately 41.14% over the past 52 weeks. The 50-day moving average sits at 10.24, while the 200-day moving average is 11.80.

As of June 30, 2026, Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A holds 1.07B in cash and equivalents against 1.21B in total debt, resulting in a net debt position of 305.20M. Total book value stands at 8.06B, with working capital of 2.63B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A paid dividends of 0.02 per share.

Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A's most recent stock split took place on June 4, 2025 with a 10:13 split ratio.